HCP Support & Resources

Guidance for you, your staff, and your patients

Adrenocortical carcinoma (ACC) may be a rare form of cancer, but you and your patients are never alone. The following resources are available to help support your staff and patients.

Access and Specialty Pharmacy

Walgreens Specialty Pharmacy is the exclusive pharmacy for Lysodren^® prescriptions. You can send your prescriptions by:

e-Prescribe to Walgreens Specialty Pharmacy

FAX the prescription to
1-866-889-1510

Call 1-800-320-2112
M-F 8 am - 8 pm,
Sat. 8 am - 5 pm, EST

Or, download the Lysodren^® prescription form here.

Dedicated to Patients
Walgreens Specialty Pharmacy will:

Check on patients after 10 days of initial treatment to address any questions
Contact patients before each refill
Review patient profiles each month
Have a pharmacist available to answer any questions

Financial Assistance
Patients with commercial insurance coverage typically pay no more than $80 per month for Lysodren^®.
If your patients are denied or lack coverage, additional financial assistance programs may be available to qualifying patients. Please have your patients call [1-844-LYSODREN] [(1-844-597-6373)] to see if they qualify.

Hospital and Institutional Orders
Please contact Direct Success by calling 1-844-597-6373 or emailing Distribution@DSuccess.com

Resources for Your Patients and Their Caregivers

Use these downloadable resources to help guide your patients and their caregivers during their Lysodren^® treatment journey.

Patient Guidebook:

Helpful guide for understanding ACC and treatment with Lysodren®, including dosage and appointment trackers

Download now

Pediatric ACC Brochure

A helpful guide for understanding ACC, designed specifically for pediatric patients or adult patient’s young family members.

Download now

Patient Advocacy Organizations

Support is also available to patients and caregivers from the following organizations:

Let’s Cure ACC >

Let’s Cure ACC provides resources, guides, and ways to connect with ACC patients and caregivers.

Adrenal Cure Collective >

Adrenal Cure Collective is a non-profit organization that aims to improve the treatment and research of adrenocortical carcinoma.

ACC Warriors >

ACC Warriors builds awareness around this rare disease, shares stories of “ACC Warriors,” and features fundraising events to help ACC families.

ACC Connections >

ACC Connections features videos, content, and social media channels to help patients and caregivers access the care they need in their fight against ACC.

National Adrenal Diseases Foundation >

National Adrenal Diseases Foundation presents access to educational resources, support for patients and caregivers, and research on adrenal diseases.

American Cancer Society >

American Cancer Society offers support and information for cancer patients, caregivers, and healthcare professionals.

PAN Foundation >

PAN Foundation helps patients with life-threating and rare diseases to fund their out-of-pocket costs with financial assistance for medications and treatments.

International Neuroendocrine Cancer Alliance >

International Neuroendocrine Cancer Alliance (INCA) works with global communities from around the world to support patient access, raise awareness, and promote research.

READ MORE ⇧

Warning/Adrenal crisis in the setting of shock, severe trauma or infection: Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs.

LYSODREN^® is an adrenal cytotoxic agent indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC).

Warning/Adrenal crisis in the setting of shock, severe trauma or infection: Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death.
If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs.

Adrenal Insufficiency and Adrenal Crisis: Temporarily withhold LYSODREN during shock; trauma, infection or adrenal insufficiency. Steroid replacement may be necessary.

Central Nervous System (CNS) Toxicity: Monitor behavioral and neurologic assessments and mitotane plasma levels at regular intervals. Mitotane plasma levels exceeding 20 mg/L are associated with a greater incidence of toxicity. Advise patients not to drive or operate hazardous machinery if experiencing CNS adverse reactions.

Ovarian Macrocysts in Premenopausal Women: Monitor pelvic ultrasound at baseline and at regular intervals. Withhold, reduce the dose, or permanently discontinue LYSODREN based on severity.

Hematologic Toxicity: Monitor complete blood counts prior to starting LYSODREN, during dose titration and as clinically indicated. Withhold, reduce the dose or permanently discontinue based on severity.

Prolonged Bleeding Time: Prolonged bleeding time has occurred in patients treated with mitotane and this should be taken into account when surgery is considered.

Embryo-Fetal Toxicity: LYSODREN can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective nonhormonal contraception.

Lactation: Advise not to breastfeed.

Hepatic Impairment: LYSODREN is not recommended for patients with severe hepatic impairment. In patients with mild to moderate hepatic impairment, monitor mitotane plasma levels frequently and modify the dosage as needed.

Renal Impairment: LYSODREN^® is not recommended for patients with severe renal impairment. In patients with mild or moderate renal impairment, monitor mitotane plasma levels frequently and modify the dosage as needed.

Most common adverse reactions include: anorexia, epigastric discomfort, nausea, vomiting diarrhea, depression, dizziness, vertigo, rash, hypercholesterolemia, hypertriglyceridemia, hypothyroidism and decreased blood free testosterone in males. LYSODREN is a hazardous drug. Advise caregivers to wear disposable gloves when handling LYSODREN tablets.

Avoid concomitant use with spironolactone, certain CYP3A substrates, hormonal contraceptives and warfarin.

Please see Full Prescribing Information, including BOXED WARNING, for LYSODREN^® (mitotane) tablets.

To report SUSPECTED ADVERSE REACTIONS, contact Direct Success Pharmacy, Inc. at 1-844-LYSODREN (1-844-597-6373) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Link to US Prescribing Information including Boxed Warning.

ESTEVE.
Passeig de la Zona Franca, 109, 4a planta, 08038 Barcelona
Tel: +34 93 446 60 00 / Fax: +34 93 347 39 44

©2025 ESTEVE.
Lysodren a registered trademark of ESTEVE
Privacy Notice | Cookie Statement
Last updated: October 2025; 0097-10/2026@ESTEVE

Support & Resources

Guidance for you, your staff, and your patients

Access and Specialty Pharmacy

Resources for Your Patients and Their Caregivers

Patient Advocacy Organizations

You are now leaving Lysodren